Abstract
Synthetic scaffolding has been used in the treatment of bone defects and fractures for over 100 years. They remain a critical tool in the treatment of large-volume bone defects, and their role as potential substitues for human bone graft continues to expand. Various materials are used commercially to produce osteoconductive scaffolds including ceramics (both bioactive and bioinert) and select polymers, all of which offer distinct advantages and dissadvantages. While currently used principally as osteoconductive conduits for growth, the role of bone-graft substitues in fracture treatment is likely to change, as biomaterial research moves towards utilizing current and future scaffold materials as delivery systems for biologic fracture treatments.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
